FOR IMMEDIATE RELEASE

GLYCART Biotechnology Appoints William J. Jenkins to Board of Directors

Zürich, Switzerland (April 28, 2004) – GLYCART Biotechnology, a privately held company leveraging a novel technology to enhance the activity of therapeutic antibodies for the treatment of cancer and autoimmune diseases (*GlycoMAb*^{TM}), today announced that William J. Jenkins, MA, MSc, MD, FRCP has joined the company's board of directors.

Dr. Jenkins has been a consultant to pharmaceutical companies, investment funds and venture capital firms in the health care sector since 1999 as well as being a member of the board of several companies in this sector. From 1997 to 1999 he was Head of Clinical Development & Regulatory Affairs for Novartis Pharma AG having held the same position pre-merger at Ciba-Geigy since 1992. Dr. Jenkins oversaw the development, registration and approval of several new drugs while at Ciba-Geigy and Novartis including Diovan, Femara and Simulect. Previously he was Head of Global Clinical Research at Glaxo, where he oversaw the clinical development, registration and approval of drugs such as Zofran, Imigran, Serevent and Fluticasone. Before that he was a Deputy Head of the UK Medicines Regulatory Authority, which he joined after 12 years in academic medicine. Dr. Jenkins said "I am enthusiastic about joining the board of GLYCART because their approach to modifying monoclonal antibodies with the aim of making them more potent and potentially more effective is both clinically and commercially attractive."

"We are delighted to welcome Dr. Jenkins, an internationally renowned pharma top manager, to our board. I am convinced that GLYCART will benefit from Dr. Jenkins's longstanding experience and his know-how, particularly regarding clinical development and regulatory affairs", said Joël Jean-Mairet, PhD, CEO of GLYCART. "There is no doubt that his hands-on involvement will be invaluable to GLYCART as we continue to drive our next-generation therapeutic antibody product candidates into clinical development for a number of indications."

"It is a great success for GLYCART to have attracted such a high calibre clinical development expert as an active board member. This valuable addition is in line with GLYCART's strategy to become an integrated therapeutic antibody research & development company. We believe firmly that Dr. Jenkins, through his exceptional expertise and his large network, will make a major contribution to GLYCART as the company achieves its full potential. We are very pleased to have him on board" commented Klaus Breiner, PhD, Investment Manager of Global Life Science Ventures and a member of GLYCART's board of directors.

About GLYCART:
GLYCART is a privately held Swiss biotechnology company focussed on the development and commercialization of a new generation of antibody products based on its proprietary GlycoMAb™ technology. GLYCART is developing its own GlycoMAb™-based antibody portfolio by in-licensing and acquiring antibodies at early stage of development and applying its proprietary GlycoMAb™ technology to them. The first products are next-generation antibody therapeutics against well-characterized and clinically validated targets. GLYCART is conducting preclinical and early clinical development studies, while actively seeking pharmaceutical and biotech partners to complete clinical development and commercialization. Taking advantage of its broad technology platform, GLYCART is also establishing collaborations and partnerships with biotech and pharmaceutical companies to enhance the efficacy and utility of their antibody drug candidates. GLYCART was founded in 2000 as a spin-off from the Swiss Federal Institute of Technology (ETH) at Zürich, and is located in Zürich-Schlieren.

About *GlycoMAb™*:
GlycoMAb is a fully developed, broad technology platform that efficiently increases the specific biological activity of therapeutic monoclonal antibodies for target cell ablation. It is based on an active modulation of antibody glycosylation during production leading to antibody products with increased ADCC (antibody-dependent cellular cytotoxicity). A high relevance for therapeutic efficacy, industrial scale applicability, broad patent protection and an extensive body of proof (including external validation) are the distinct hallmarks of this technology.

For further information please contact:

GLYCART Biotechnology AG
Joël Jean-Mairet, PhD
Chief Executive Officer
Tel. +41 1 755 6167
Fax: +41 1 755 6160
joel.jean-mairet@glycart.com
Website: www.glycart.com

For media inquiries please contact:

Rochat & Partners
Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
clamps@rochat-pr.ch